Breast cancer
TEXT trail | 2014 | HR+ endocrine |
Meta-analysis of AI vs TAM in early breast cancer | 2015 | HR+ endocrine |
SOFT trial | 2015 | HR+ endocrine |
MA-17R | 2016 | HR+ endocrine |
FACE trial | 2017 | HR+ endocrine |
IDEAL (BOOG 2006-05) trial | 2018 | HR+ endocrine |
SOLE trial | 2018 | HR+ endocrine |
ABCSG-16 trial (SALSA) trial | 2021 | HR+ endocrine |
NSABP B-06 trial | 2002 | Miscellaneous |
NSABP B-04 trial | 2002 | Miscellaneous |
IMpassion130 | 2021 | TNBC advanced |
ASCENT Trial | 2021 | TNBC advanced |
TEXT trail
Pagani O et al, NEJM, 2014; PMID: 24881463
HR+ endocrine
Background: included 4690 premenopausal women with HR+ early breast cancer
Arm A: Tamoxifen 20mg daily with ovarian function suppression (OFS)
Arm B: Exemestane 25mg daily with OFS
OFS was achieved by gonadotropin- releasing-hormone (GnRH) agonist triptorelin 3.75mg IM q28d , bilateral oophorectomy, or bilateral ovarian irradiation.
mFollow up: 68mo (~5.6yr)
5-yr DFS: 91.1% vs 87.3% for AI+OFS vs TAM+OFS (HR for disease recurrence, second invasive cancer, or death 0.72, 95%CI 0.60-0.85, P<.001).
Freedom from breast cancer at 5yr: 92.8% vs 88.8% for AI+OFS vs TAM+OFS (HR 0.66, 95%CI 0.55-0.80, P<.001).
mOS: HR, 1.14; 95%CI 0.86-1.51; P=.37
Conclusions: AI + OFS (vs TAM+OFS) is more efficient in decreasing recurrence of breast cancer. Importantly, OFS provides benefit only in high-risk breast cancer patients (Stage II and III, high risk biologic features) especially in women < 35yr old.
Summarized by Veli Bakalov, MD